AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Dec 2013 07:14 AM
RNS
Top Line Results From Phase III Study of Lesinurad
13 Dec 2013 07:00 AM
RNS
FDA Advisory Committee Recommends Dapagliflozin
12 Dec 2013 07:00 AM
RNS
FDA Advisory Committee Votes on Metreleptin
06 Dec 2013 07:00 AM
RNS
European Commission Approves Fluenz Tetra
02 Dec 2013 03:00 PM
RNS
Blocklisting Interim Review
02 Dec 2013 01:00 PM
RNS
Total Voting Rights
22 Nov 2013 01:42 PM
RNS
XIGDUO POSITIVE CHMP OPINION FOR TYPE 2 DIABETES
19 Nov 2013 07:00 AM
RNS
NDA for Naloxegol accepted by US FDA
01 Nov 2013 04:00 PM
RNS
Total Voting Rights
01 Nov 2013 01:45 PM
RNS
Director/PDMR Shareholding
31 Oct 2013 07:02 AM
RNS
US Court Decision in Pulmicort Respules Litigation
31 Oct 2013 07:01 AM
RNS
Marc Dunoyer Appointed Chief Financial Officer
31 Oct 2013 07:00 AM
RNS
3rd Quarter Results
30 Oct 2013 09:00 AM
RNS
Notice of Results
30 Oct 2013 07:00 AM
RNS
ASTRAZENECA ADVANCES BENRALIZUMAB TO PHASE III
22 Oct 2013 07:00 AM
RNS
AstraZeneca starts phase III study for selumetinib
15 Oct 2013 07:00 AM
RNS
Medimmune acquires Spirogen
07 Oct 2013 07:00 AM
RNS
MedImmune completes Amplimmune acquisition
01 Oct 2013 04:00 PM
RNS
Total Voting Rights
30 Sep 2013 07:01 AM
RNS
MAA FOR OLAPARIB ACCEPTED BY EMA
27 Sep 2013 07:00 AM
RNS
MAA APPLICATION FOR NALOXEGOL ACCEPTED
20 Sep 2013 12:54 PM
RNS
Fluenz Tetra receives positive CHMP opinion in EU
04 Sep 2013 07:00 AM
RNS
Starts phase III clinical programme for olaparib
02 Sep 2013 03:00 PM
RNS
Total Voting Rights
27 Aug 2013 07:00 AM
RNS
MEDIMMUNE ACQUIRES AMPLIMMUNE
01 Aug 2013 04:00 PM
RNS
Total Voting Rights
01 Aug 2013 03:00 PM
RNS
Director/PDMR Shareholding
01 Aug 2013 07:00 AM
RNS
Half Yearly Pipeline Update
01 Aug 2013 07:00 AM
RNS
Half Yearly Report
31 Jul 2013 09:00 AM
RNS
Notice of Results
31 Jul 2013 07:00 AM
RNS
Collaborates with FibroGen on anaemia treatment
26 Jul 2013 07:00 AM
RNS
FDA receipt of dapagliflozin resubmission
19 Jul 2013 07:00 AM
RNS
AstraZeneca completes acquisition of Omthera
15 Jul 2013 07:00 AM
RNS
Simon Lowth, CFO, to leave AstraZeneca
11 Jul 2013 04:30 PM
RNS
Holding(s) in Company
01 Jul 2013 03:00 PM
RNS
Total Voting Rights
28 Jun 2013 05:35 PM
RNS
Publication of Prospectus
28 Jun 2013 07:00 AM
RNS
Completes Acquisition of Pearl Therapeutics
19 Jun 2013 07:00 AM
RNS
Announces top-line results for SAVOR study
12 Jun 2013 03:00 PM
RNS
Director/PDMR Shareholding
12 Jun 2013 03:00 PM
RNS
Director/PDMR Shareholding
12 Jun 2013 03:00 PM
RNS
Director/PDMR Shareholding
10 Jun 2013 07:00 AM
RNS
To Acquire Pearl Therapeutics
04 Jun 2013 07:00 AM
RNS
Top-line results from Phase III Oskira trials
03 Jun 2013 01:00 PM
RNS
Blocklisting Interim Review
03 Jun 2013 12:00 PM
RNS
Total Voting Rights
28 May 2013 07:00 AM
RNS
Appeal against generic PULMICORT RESPULES
28 May 2013 07:00 AM
RNS
Acquires Omthera Pharmaceuticals
14 May 2013 02:00 PM
RNS
Director/PDMR Shareholding
08 May 2013 02:00 PM
RNS
Director/PDMR Shareholding

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings